Lucia Del Mastro

Summary

Affiliation: National Cancer Research Institute
Country: Italy

Publications

  1. ncbi Is it possible to use anthracyclines in patients older than 70 years? Contra
    Lucia Del Mastro
    Istituto Nazionale per la Ricerca sul Cancro, Genoa
    Tumori 88:S136-7. 2002
  2. doi Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial
    Lucia Del Mastro
    S S Sviluppo Terapie Innovative, Oncologia Medica A, Istituto Nazionale per la Ricerca sul Cancro, L go R Benzi 10, 16132 Genova, Italy
    JAMA 306:269-76. 2011
  3. pmc Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study
    Matteo Clavarezza
    Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy
    BMC Cancer 12:216. 2012
  4. pmc Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
    Lucia Del Mastro
    IRCCS AOU San Martino IST National Institute for Cancer Research, UO Sviluppo Terapie Innovative, Genoa, Italy
    BMC Cancer 13:164. 2013
  5. doi Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Lucia Del Mastro
    Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martini IST, Largo Rosanna Benzi, 10, 16132, Genova, Italy
    Expert Rev Anticancer Ther 12:1391-405. 2012
  6. ncbi Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group
    L Del Mastro
    Oncologia Medica A, Istituto Nazionale per Ricerca sul Cancro, Largo Rosanna Benzi, Genova, Italy
    Ann Oncol 19:299-307. 2008
  7. ncbi Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
    L Del Mastro
    Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 17:74-8. 2006
  8. pmc HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
    L Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Genoa, Italy
    Br J Cancer 93:7-14. 2005
  9. doi Medical approaches to preservation of fertility in female cancer patients
    Lucia Del Mastro
    SS Sviluppo Terapie Innovative, National Institute for Cancer Research, Genova, Italy
    Expert Opin Pharmacother 12:387-96. 2011
  10. ncbi Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
    L Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, 16132 Genoa, Italy
    Ann Oncol 16:253-8. 2005

Detail Information

Publications36

  1. ncbi Is it possible to use anthracyclines in patients older than 70 years? Contra
    Lucia Del Mastro
    Istituto Nazionale per la Ricerca sul Cancro, Genoa
    Tumori 88:S136-7. 2002
  2. doi Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial
    Lucia Del Mastro
    S S Sviluppo Terapie Innovative, Oncologia Medica A, Istituto Nazionale per la Ricerca sul Cancro, L go R Benzi 10, 16132 Genova, Italy
    JAMA 306:269-76. 2011
    ..Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available...
  3. pmc Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study
    Matteo Clavarezza
    Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy
    BMC Cancer 12:216. 2012
    ..International treatment guidelines recommend administration of adjuvant chemotherapy in early breast cancer based on clinical, prognostic and predictive parameters...
  4. pmc Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
    Lucia Del Mastro
    IRCCS AOU San Martino IST National Institute for Cancer Research, UO Sviluppo Terapie Innovative, Genoa, Italy
    BMC Cancer 13:164. 2013
    ..This open-label study compared docetaxel/gemcitabine vs. paclitaxel/gemcitabine and a weekly (W) vs. 3-weekly (3 W) schedule in metastatic breast cancer (MBC)...
  5. doi Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Lucia Del Mastro
    Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martini IST, Largo Rosanna Benzi, 10, 16132, Genova, Italy
    Expert Rev Anticancer Ther 12:1391-405. 2012
    ..This review is focused on the available results obtained with the use of trastuzumab in the subset of HER2-positive breast cancer patients with metastatic disease...
  6. ncbi Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group
    L Del Mastro
    Oncologia Medica A, Istituto Nazionale per Ricerca sul Cancro, Largo Rosanna Benzi, Genova, Italy
    Ann Oncol 19:299-307. 2008
    ..We analyzed the outcome of both pre- and postmenopausal women who entered two randomized trials (Gruppo Oncologico Nord-Ovest-Mammella Intergruppo studies) on adjuvant chemotherapy and received either concomitant or sequential TAM...
  7. ncbi Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
    L Del Mastro
    Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 17:74-8. 2006
    ..This phase II study aimed to assess the activity of such a method in young, breast cancer patients undergoing adjuvant chemotherapy...
  8. pmc HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
    L Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Genoa, Italy
    Br J Cancer 93:7-14. 2005
    ..Our data suggest a potential role of HER-2 overexpression in predicting the efficacy of dose-dense epirubicin-containing chemotherapy and the need to confirm this hypothesis in future prospective studies...
  9. doi Medical approaches to preservation of fertility in female cancer patients
    Lucia Del Mastro
    SS Sviluppo Terapie Innovative, National Institute for Cancer Research, Genova, Italy
    Expert Opin Pharmacother 12:387-96. 2011
    ..the loss or impairment of ovarian function is an irreversible side effect that can occur in young cancer patients undergoing anticancer treatments. Its incidence varies according to the type of chemotherapy and the patient's age...
  10. ncbi Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
    L Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, 16132 Genoa, Italy
    Ann Oncol 16:253-8. 2005
    ..First-line chemotherapy regimens suitable for elderly advanced breast cancer patients are still not defined...
  11. doi Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives
    Lucia Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, Genoa, Italy
    Cancer Treat Rev 37:208-11. 2011
    ....
  12. ncbi Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors
    Lucia Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, L go R Benzi 10, 16132 Genoa, Italy
    Cancer Treat Rev 33:681-7. 2007
    ..Here, we review recent updated results obtained with AIs as adjuvant therapy, in terms of reducing the risk of distant metastases...
  13. ncbi Infertility and pregnancy after breast cancer: current knowledge and future perspectives
    Lucia Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, 16132 Genova, Italy
    Cancer Treat Rev 32:417-22. 2006
    ....
  14. ncbi Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma
    Marco Venturini
    Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Cancer 97:1174-80. 2003
    ..The objective of this study was to evaluate the activity and safety of oral capecitabine in combination with docetaxel and epirubicin (TEX) as first-line treatment for patients with locally advanced/metastatic breast carcinoma...
  15. ncbi Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials
    Lucia Del Mastro
    UO Development of Innovative Therapies, Medical Oncology Department, IRCCS AOU San Martino IST, National Institute for Cancer Research, Genova, Italy Electronic address
    Cancer Treat Rev 40:675-83. 2014
    ..We conducted a systematic review and meta-analysis of randomized trials evaluating the efficacy of GnRHa, given before and during chemotherapy, in the prevention of POF in premenopausal cancer patients...
  16. ncbi [The AIOM (Italian Association of Medical Oncology) practice guidelines for breast neoplasms]
    Lucia Del Mastro
    Oncologia Medica A, Istituto Nazionale per la Ricerca sul Cancro, Genova
    Tumori 90:1-8. 2004
  17. ncbi Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer
    Alessia Levaggi
    Innovative Therapies Development Unit Department of Medical Oncology, IRCCS AOU San Martino IST National Institute for Cancer Research, Genoa, Italy
    Anticancer Res 34:3715-20. 2014
    ..Pre-treatment serum detection of viral hepatitis B and C antigens and antibodies may be useful in the adjuvant therapy decision-making process and for adequate monitoring of liver function during antineoplastic therapy. ..
  18. ncbi Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
    Paolo Bruzzi
    Unit of Clinical Epidemiology, National Institute for Cancer Research, Largo Rosanna Benzi 10, 16132 Genoa, Italy
    J Clin Oncol 23:5117-25. 2005
    ..To assess the validity of objective response to chemotherapy as a surrogate end point for survival in metastatic breast cancer...
  19. pmc Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study
    Matteo Clavarezza
    E O Ospedali Galliera, Genoa, Italy
    Oncologist 18:924-5. 2013
    ..Adjuvant dose-dense (DD) chemotherapy is more effective than regimens administered every 3 weeks, especially in hormonal receptor (HR)-negative tumors...
  20. doi Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients
    Claudia Bighin
    Department of Medical Oncology, IRCCS Istituto di Ricovero and Cura a Carattere Scientifico AOU Azienda Ospedaliera Universitaria San Martino IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Future Oncol 9:955-7. 2013
    ..TDM-1 is superior and less toxic than lapatinib plus capecitabine in metastatic breast cancer patients previously treated with trastuzumab and taxanes, and its role as a first-line therapy is currently under investigation...
  21. ncbi Sentinel lymph node biopsy in breast cancer patients: the medical oncology perspective
    Tiziana Catzeddu
    Division of Medical Oncology, National Cancer Reasearch Institute, Genoa, Italy
    J Surg Oncol 85:129-32. 2004
    ..The new version of the staging system of breast cancer has recognised the need for a standard diagnostic approach and of a nomenclature system which also takes SLNB into account...
  22. ncbi [Epoetin in cancer patients. Guidelines of the ASCO and the ASH for evidence-based clinical practice]
    Lucia Del Mastro
    Oncologia Medica A, Istituto Nazionale per la Ricerca su Cancro, Genova
    Tumori 89:1-12. 2003
  23. ncbi Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial
    Marco Venturini
    Institution of Oncologia Medica, Sperimentazioni Cliniche Controllate Istituto Nazionale per la Ricerca sul Cancro, Genova PB, Italy
    J Natl Cancer Inst 97:1724-33. 2005
    ....
  24. ncbi Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab
    Barbara Cardinali
    Development of Innovative Therapies Unit, IRCCS AOU San Martino IST, 16132, Genoa, Italy
    Anal Bioanal Chem 406:4557-61. 2014
    ..The procedure was also tested in sera obtained from breast cancer patients to evaluate trastuzumab serum levels, confirming the applicability of method that could be a valid assay to use in daily laboratory practice. ..
  25. pmc Fertility counseling of young breast cancer patients
    Matteo Lambertini
    S C Oncologia Medica A, IRCCS AOU San Martino IST, Genova, Italy
    J Thorac Dis 5:S68-80. 2013
    ....
  26. doi Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients
    Claudia Bozza
    Department of Oncology, University Hospital of Udine, Udine, Italy Department of Medical and Biological Sciences, University of Udine, Udine, Italy Department of Medical Oncology UO Oncologia Medica A, IRCCS AOU San Martino IST, Largo Rosanna Benzi, 10, 16132 Genova, Italy Department of Radiation Oncology, New York University School of Medicine, New York, New York, USA Mother and Child Department, Pordenone Hospital, Pordenone, Italy Department of Medical Oncology SS Sviluppo Terapie Innovative, IRCCS AOU San Martino IST, Genova, Italy
    Endocr Relat Cancer 21:R51-65. 2014
    ..Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH. ..
  27. ncbi Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and beta2-microglobulin downregulation in breast cancer
    Anna Morabito
    Breast Cancer Laboratory of Tumour Genetics Unit, National Cancer Research Institute, Genoa, Italy
    Hum Immunol 70:492-5. 2009
    ..This result may correlate with the role of beta2-m in regulating cancer cell growth...
  28. ncbi Weekly paclitaxel in elderly patients with advanced breast cancer: a dose-finding study
    Lazzaro Repetto
    Unità Operativa di Oncologia INRCA, Rome, Italy
    Drugs R D 5:11-5. 2004
  29. ncbi ATAC trial update
    Lucia Del Mastro
    Lancet 365:1225; author reply 1225-6. 2005
  30. ncbi Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer
    Gianfilippo Bertelli
    South West Wales Cancer Institute, University of Wales Swansea, Swansea, UK
    Oncology 68:364-70. 2005
    ..We investigated the effects of the third-generation aromatase inhibitor letrozole as a maintenance therapy in postmenopausal patients who had responded or had stable disease with first-line chemotherapy...
  31. doi Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
    Diana Crivellari
    IBCSG Coordinating Center, Effingerstrasse 40, CH 3008 Bern, Switzerland
    J Clin Oncol 26:1972-9. 2008
    ..To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial...
  32. ncbi Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer
    Gianfilippo Bertelli
    South West Wales Cancer Institute, Swansea, United Kingdom
    Oncology 69:471-7. 2005
    ..If exemestane is used as first anti-aromatase agent, however, it is unclear whether patients can still benefit from letrozole or anastrozole after progression...
  33. ncbi Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
    Alan S Coates
    International Breast Cancer Study Group IBCSG, IBCSG Coordinating Center, Bern, Switzerland
    J Clin Oncol 25:486-92. 2007
    ..Because this presentation may unduly reflect early events, the present analysis is limited to patients randomly assigned to the continuous therapy arms and includes protocol-defined updated results...
  34. ncbi Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 63:53-64. 2007
    ..A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer...
  35. ncbi Fertility preservation strategies for breast cancer patients
    Lucia Del Mastro
    J Clin Oncol 24:4220-1; author reply 4221-2. 2006
  36. ncbi Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Matteo Clavarezza
    J Natl Cancer Inst 99:1050-1; author reply 1051-2. 2007